Humacyte, Inc. Receives Nasdaq Compliance Confirmation: Shareholder Update
Key Points:
- Humacyte, Inc. received a compliance notification from Nasdaq regarding the minimum bid price requirement for continued listing.
- The company’s common stock had previously closed below the \$1.00 minimum price for 30 consecutive business days, triggering a compliance review.
- To regain compliance, the stock needed to close at or above \$1.00 for at least 10 consecutive business days prior to November 2, 2026.
- As of June 5, 2026, Humacyte remains listed on The Nasdaq Stock Market LLC under the ticker symbol HUMA for common stock and HUMAW for redeemable warrants.
Details for Investors:
- Background: On May 4, 2026, Humacyte received a letter from Nasdaq staff indicating its common stock had closed below the \$1.00 minimum bid price for 30 consecutive business days ending May 1, 2026.
- Compliance Requirement: Nasdaq Listing Rule 5450(a)(1) requires the closing bid price of Humacyte’s common stock to be at least \$1.00 per share for a minimum of 10 consecutive business days. Failure to meet this requirement would risk delisting.
- Timeframe for Compliance: The company had until November 2, 2026 to regain compliance and avoid Nasdaq delisting.
- Shareholder Impact: If the company were unable to regain compliance, its shares could be delisted from Nasdaq, which would likely have a significant negative impact on liquidity, investor confidence, and potentially the share price.
- Current Status: As of June 5, 2026, Humacyte remains listed on Nasdaq. No indication is given in this report that compliance was lost or that delisting is imminent, but shareholders should remain vigilant regarding future updates.
- Securities Registered:
- Common Stock: Par value \$0.0001 per share, trading symbol HUMA, listed on Nasdaq.
- Redeemable Warrants: Each warrant exercisable for one share of common stock at an exercise price of \$11.50, trading symbol HUMAW, listed on Nasdaq.
- Emerging Growth Company Status: The company is not an emerging growth company.
- No Written Communications, Soliciting Material, or Tender Offers: The filing is not intended to satisfy written communications under Rule 425, soliciting material under Rule 14a-12, or pre-commencement communications under Rule 14d-2(b) or Rule 13e-4(c).
Important Shareholder Considerations:
- Price Sensitivity: The risk of delisting due to non-compliance with Nasdaq’s minimum bid price rule is a significant price-sensitive issue. If Humacyte fails to maintain compliance, the share price could drop sharply due to reduced liquidity and market confidence.
- Regulatory Risk: Investors should monitor further company communications and Nasdaq filings closely for updates regarding compliance status.
- Trading Symbols and Securities: Humacyte’s securities remain actively listed and traded on Nasdaq, which is positive for current shareholders, but this situation requires ongoing vigilance.
Conclusion:
While Humacyte is currently compliant and remains listed on Nasdaq, shareholders should be aware of the recent compliance notification and the risk factors associated with minimum bid price requirements. Continued vigilance is warranted, as any future failure to meet Nasdaq standards could result in delisting and a significant negative impact on share value.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with a financial advisor before making investment decisions. The information provided is based on public filings as of June 5, 2026 and may be subject to change.
